BK Virus and Renal Dysfunction in Postoperative/Posttraumatic Critically Ill Patients (BICUK)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Ulm, Germany, 89070
- Clinic of Anesthesiology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Critically ill, postoperative/posttraumatic patients with threatening acute renal failure
Exclusion Criteria:
- Life expectancy < 24 hours
- Participation in other trials
- Known or suspected pregnancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Patients with non-septic shock
Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
|
|
Patients with septic shock
Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Association between BK virus reactivation and acute renal dysfunction
Time Frame: Daily monitoring of acute renal failure, first day of acute renal dysfunction, first days on hemodiafiltration, first day after hemodiafiltration, before demission from intensive care unit or death.
|
Daily monitoring of acute renal failure, first day of acute renal dysfunction, first days on hemodiafiltration, first day after hemodiafiltration, before demission from intensive care unit or death.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pattern of biomarkers and surface markers on leukocytes.
Time Frame: First day of acute renal dysfunction, first days on hemodiafiltration, first day after hemodiafiltration, before demission from intensive care unit or death.
|
First day of acute renal dysfunction, first days on hemodiafiltration, first day after hemodiafiltration, before demission from intensive care unit or death.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Manfred Weiss, MD, MBA, University Hospital Ulm
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
- BK virus
- patients
- biomarkers
- surgery
- complement
- outcome
- infections
- shock
- inflammation
- sepsis
- mortality
- systemic inflammatory response syndrome
- cytokines
- SIRS
- severe sepsis
- humans
- inflammatory response
- cell surface markers
- functional polymorphisms
- length of stay
- polytrauma
- hemodiafiltration
- acute renal failure
- organ dysfunctions
- SOFA
- severity of disease
- APACHEII
- SAPSII
- SPAPS3
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Anae_ICU_Ulm_BKV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.